CY1118570T1 - Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου - Google Patents

Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου

Info

Publication number
CY1118570T1
CY1118570T1 CY20171100139T CY171100139T CY1118570T1 CY 1118570 T1 CY1118570 T1 CY 1118570T1 CY 20171100139 T CY20171100139 T CY 20171100139T CY 171100139 T CY171100139 T CY 171100139T CY 1118570 T1 CY1118570 T1 CY 1118570T1
Authority
CY
Cyprus
Prior art keywords
acid
treatment
composition
alphantanyl
new
Prior art date
Application number
CY20171100139T
Other languages
English (en)
Inventor
Anders Pettersson
Emil Schwan
Barbro Johansson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118570(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of CY1118570T1 publication Critical patent/CY1118570T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

Παρέχονται φαρμακευτικές συνθέσεις για την αγωγή του πόνου λ.χ. βραχυπρόθεσμου πόνου, οι οποίες συνθέσεις περιλαμβάνουν ένα μείγμα που περιλαμβάνει: (a) μικροσωματίδια αλφαιντανύλης, ή ενός φαρμακευτικά αποδεκτού άλατος αυτής, τα οποία μικροσωματίδια παρουσιάζονται επί των επιφανειών μεγαλύτερων σωματιδίων-φορέων• (b) μία υδατοδιαλυτή ασθενή βάση• και (c) μία ένωση η οποία είναι ένα ασθενές οξύ, το οποίο οξύ παρουσιάζεται σε στενή ανάμειξη με τα μικροσωματίδια αλφαιντανύλης ή άλατος αυτής. Η σύνθεση μπορεί περαιτέρω να περιλαμβάνει ένα μέσο καταθρυμματισμού. Το οξύ είναι κατά προτίμηση κιτρικό οξύ.
CY20171100139T 2012-05-02 2017-01-31 Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου CY1118570T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition
PCT/GB2013/051131 WO2013164620A1 (en) 2012-05-02 2013-05-01 New alfentanil composition for the treatment of acute pain

Publications (1)

Publication Number Publication Date
CY1118570T1 true CY1118570T1 (el) 2017-07-12

Family

ID=48577134

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100139T CY1118570T1 (el) 2012-05-02 2017-01-31 Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου
CY181101154T CY1120820T1 (el) 2012-05-02 2018-11-05 Νεα συνθεση αλβαιντανυλης για την αγωγη του οξεος πονου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101154T CY1120820T1 (el) 2012-05-02 2018-11-05 Νεα συνθεση αλβαιντανυλης για την αγωγη του οξεος πονου

Country Status (34)

Country Link
US (4) US8815911B2 (el)
EP (2) EP3150199B1 (el)
JP (1) JP6275696B2 (el)
KR (1) KR20150005695A (el)
CN (1) CN104427978B (el)
AU (1) AU2013255640B2 (el)
BR (1) BR112014027213A8 (el)
CA (1) CA2871805A1 (el)
CL (1) CL2014002979A1 (el)
CO (1) CO7170181A2 (el)
CY (2) CY1118570T1 (el)
DK (2) DK3150199T3 (el)
EA (1) EA028110B1 (el)
ES (2) ES2694644T3 (el)
HK (1) HK1203399A1 (el)
HR (2) HRP20161634T1 (el)
HU (1) HUE031792T2 (el)
IL (1) IL235272B (el)
IN (1) IN2014MN02156A (el)
LT (2) LT3150199T (el)
ME (1) ME02644B (el)
MX (1) MX360665B (el)
NZ (1) NZ701428A (el)
PE (1) PE20142444A1 (el)
PH (1) PH12014502407A1 (el)
PL (2) PL3150199T3 (el)
PT (2) PT2849730T (el)
RS (2) RS57951B1 (el)
SG (1) SG11201407081PA (el)
SI (2) SI3150199T1 (el)
SM (1) SMT201700086B (el)
TR (1) TR201815935T4 (el)
WO (1) WO2013164620A1 (el)
ZA (1) ZA201407559B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2706986E (pt) 2011-09-19 2015-07-07 Orexo Ab Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos
EP3150199B1 (en) * 2012-05-02 2018-08-08 Orexo AB New alfentanil composition for the treatment of acute pain
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109A (zh) * 2022-06-17 2022-09-13 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
RU2345791C2 (ru) 2003-01-31 2009-02-10 Орексо Аб Быстродействующая фармацевтическая композиция
EP1599186B1 (en) 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
NZ548216A (en) 2003-12-31 2010-02-26 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
US7862833B2 (en) 2003-12-31 2011-01-04 Cima Labs, Inc. Effervescent oral opiate dosage forms and methods of administering opiates
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CA2599386A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
WO2008068471A1 (en) * 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
ES2534433T3 (es) 2007-08-07 2015-04-22 Acelrx Pharmaceuticals, Inc. Composiciones que comprenden sufentanilo y triazolam para sedación y analgesia operatorias utilizando formas farmacéuticas transmucosas orales
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
WO2010027770A1 (en) 2008-09-04 2010-03-11 Mallinckrodt Inc. Crystalline forms of sufentanil citrate
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
AU2010249047A1 (en) 2009-05-13 2011-11-24 Protein Delivery Solutions, Llc Pharmaceutical system for trans-membrane delivery
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP3150199B1 (en) * 2012-05-02 2018-08-08 Orexo AB New alfentanil composition for the treatment of acute pain

Also Published As

Publication number Publication date
PH12014502407B1 (en) 2015-01-12
MX2014013176A (es) 2015-01-19
PE20142444A1 (es) 2015-01-09
LT3150199T (lt) 2018-11-12
TR201815935T4 (tr) 2018-11-21
WO2013164620A1 (en) 2013-11-07
CN104427978B (zh) 2017-03-01
SI3150199T1 (sl) 2018-12-31
ME02644B (me) 2017-06-20
SI2849730T1 (sl) 2017-02-28
RS55489B1 (sr) 2017-04-28
HK1203399A1 (en) 2015-10-30
BR112014027213A2 (pt) 2017-06-27
US20140005223A1 (en) 2014-01-02
CO7170181A2 (es) 2015-01-28
ES2694644T3 (es) 2018-12-26
RS57951B1 (sr) 2019-01-31
SG11201407081PA (en) 2014-11-27
SMT201700086B (it) 2017-03-08
EP3150199A1 (en) 2017-04-05
US20150133501A1 (en) 2015-05-14
PL2849730T3 (pl) 2017-05-31
CL2014002979A1 (es) 2014-12-05
ES2614757T3 (es) 2017-06-01
CY1120820T1 (el) 2019-12-11
MX360665B (es) 2018-11-13
EP3150199B1 (en) 2018-08-08
BR112014027213A8 (pt) 2018-01-16
ZA201407559B (en) 2016-05-25
EP2849730A1 (en) 2015-03-25
JP6275696B2 (ja) 2018-02-14
PH12014502407A1 (en) 2015-01-12
US8815911B2 (en) 2014-08-26
NZ701428A (en) 2016-10-28
AU2013255640A1 (en) 2014-11-20
EA201401200A1 (ru) 2015-02-27
US20180214437A1 (en) 2018-08-02
PL3150199T3 (pl) 2019-03-29
EP2849730B1 (en) 2016-11-09
IL235272B (en) 2018-10-31
PT3150199T (pt) 2018-11-21
IN2014MN02156A (el) 2015-08-28
CA2871805A1 (en) 2013-11-07
HRP20181761T1 (hr) 2018-12-28
HRP20161634T1 (hr) 2017-01-13
US9345698B2 (en) 2016-05-24
DK3150199T3 (en) 2018-11-12
KR20150005695A (ko) 2015-01-14
JP2015515974A (ja) 2015-06-04
AU2013255640B2 (en) 2017-06-15
US9782396B2 (en) 2017-10-10
PT2849730T (pt) 2017-02-15
EA028110B1 (ru) 2017-10-31
DK2849730T3 (en) 2017-02-13
CN104427978A (zh) 2015-03-18
HUE031792T2 (en) 2017-07-28
US20170071927A1 (en) 2017-03-16
LT2849730T (lt) 2016-12-27

Similar Documents

Publication Publication Date Title
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1124068T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1121597T1 (el) Φαρμακοτεχνικες μορφες απιξαμπανης
CY1118570T1 (el) Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1120521T1 (el) Παρασκευασμα προμειγματος δεξμεδετομιδινης
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
PH12016500024A1 (en) Bromodomain inhibitor
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CY1126141T1 (el) Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы